Tag: LEN

Finishing Up a Solid Trading Week

CURE Pharmaceutical Holding Corp. (OTCMKTS:CURR)

As we mentioned in Wednesday morning’s premarket report, CURE officials conducted a Zoom webcast on the current state of the company yesterday afternoon. Today we just wanted to remind our readers that if you were unable to catch the presentation live, you can still get it on demand at the following link: https://zoom.us/webinar/register/WN_BrUIQ-jlR0OkoNC8GNCnhg

CURE has a lot happening right now, so we would highly suggest getting the story straight from the horse’s mouth and hearing what company directors had to say.
_______

Direct all investor inquiries on CURR to:

Gary Zwetchkenbaum
Plum Tree Consulting LLC
Phone: (718) 224-3123
Cell: (516) 455-7662
Website: www.plumtreeconsultingllc.com


Options Recaps

Our LEN and ACN idfeas from yesterday’s report panned out pretty well, and we have a couple of fresh ideas to add to the mix as well.

LEN Weekly $75.50-77 Calls
$75.50: 2.55-6.14 (+140%)
$76: 2.26-5.60 (+148%)
$76.50: 1.51-5.10 (+238%)
$77: 1.35-4.90 (+263%)
_______

ACN Weekly $255-262.50 Calls
$255: 9.99-15.00 (+50%)
$257.50: 8.19-12.30 (+50%)
$260: 5.79-10.01 (+73%)
$262.50: 4.15-9.00 (+117%)
______

Fresh Options Ideas:
WGO Weekly $60 Calls
DRI Weekly $115 Calls

Extended Watchlist:
BSRC, CEOS, SAML, TEUM, BCII, CBGH

PBIO News, Options Ideas

Pressure BioSciences, Inc. (OTCMKTS:PBIO)

We are checking in with PBIO this morning, as the company released a PR pertaining to the adoption of its Pressure Cycling Technology (PCT) in coronavirus research, which you’ll find below. We are also still awaiting news of the company’s partnership with Cannaworx, and the launch of its FDA-registered immune booster this month, as indicated by PBIO on December 4th.

Since we began tracking this stock, we have witnessed an impressive trading range as PBIO has moved from a low of 1.80 to yesterday’s new high of 2.75. That works out to an upswing of 53% inside of two weeks, and gives us plenty of reason to be interested in what comes next.

SOUTH EASTON, Mass., Dec. 17, 2020 /PRNewswire/ — Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmetics, nutraceuticals, and food & beverage industries, today announced a remarkable convergence of global research teams announcing pivotal new insights into COVID-19 biology and disease processes. These data point to potential new pathways to next generation diagnostics and treatments. All teams selected PBI’s Pressure Cycling Technology (“PCT”) platform for their critical sample preparation steps, to help ensure that the greatest abundance and diversity of reproducible results would be revealed in the thousands of proteins involved in the affected biochemical pathways. (>>View Full PR via OTCMARKETS)
_____

We also have a video presentation on the PBIO chart that we would suggest our readers take a moment to view:


PBIO Video Chart 
_____

For All Investor Inquiries on PBIO,Contact:
Gary Zwetchkenbaum, Plum Tree Consulting LLC
Email: gzplumtree@gmail.com
Phone: (516) 455-7662
Web: plumtreeconsultingllc.com 

The Toro Co. TTC – Recap 

We included the TTC Weekly $90-95 Calls as a possible options trading idea in yesterday morning’s premarket report. With the help of a solid day for the markets as a whole, and the company reporting strong figures for both Q4 and the the 2020 Fiscal Year, we saw instant results.

Here are the total possible intraday gains that were on the table for those targets: 

TTC Weekly $90-95 Calls
$90: 1.15-2.61 (+127%)
$95: .05-.15 (+200%)

_____

Fresh Options Ideas:
JBL Weekly $43.50-45 Calls
LEN Weekly $75.50-77 Calls
ACN Weekly $255-262.50 Calls

A Load of Fresh Targets

Amkor Technology, AMKR

We’re going to take a little break from our typical focus today, and have a look some pure stock plays that we feel have some good potential. So our first billing on this Monday morning is going to be AMKR.

The stock has been searching out a bottom over the last few sessions, which it has found around the upper $10-level, and has just received an upgrade and $16 price target from Credit Suisse. Accordingly, we’re going to place AMKR on extended watch for the possibility of a notable rebound from the current PPS.

Bellerophon Therapeutics, Inc. BLPH

Another stock play we’re focusing in on today is BLPH, a symbol we’ve had some experience with in the past. After a lackluster summer, the stock appears to be gearing up for a potentially fruitful fall season. It recently reversed off of a bottom, and we’re going to want to place this one on watch for an extended term as well.

BLPH tested the $20-25 range back in May, and we are going to hang around to see if it can mount a similar effort as we head into the holidays.

Kontrol Energy Corp. KNRLF

Speaking of stock plays, we had included a mention of the OTC stock KNRLF in our watchlist on Thursday morning. The low from that day came in at 2.12 and on Friday, it reached a new high of 3.88 marking a two-day swing of 83%

It also ended up closing out the week with strength very near that daily high, so we’ll have our eyes peeled for a possible continuation of that momentum.

Fresh Options Idea:
LEN Weekly $78-80 Calls 

Extended Watchlist:
CHND, RBII, HGEM, OMID, DNAX, BABL, HNCKF